A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Obesity, Overweight

In brief

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Key facts

Study ID: NCT06901349
Run by: Eli Lilly and Company
People needed: 0
Starts: 2025-05-23
Expected to finish: 2025-06-10
Last updated by the study team: 2025-09-24

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have type 2 diabetes
Have a BMI of ≥27 kilograms per square meter (kg/m2)
Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

You may not qualify if…

Have a prior or planned surgical treatment for obesity,
Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma
Have poorly controlled hypertension
Have any of the following cardiovascular conditions within 3 months prior to screening:
acute myocardial infarction
cerebrovascular accident (stroke)
unstable angina, or
hospitalization due to congestive heart failure
Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
Have renal impairment
Have a history of symptomatic gallbladder disease within the past 2 years
Have signs and symptoms of any liver disease
Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
Have a history of acute or chronic pancreatitis
Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening

Where it is running

Yuma Clinical Trials — Yuma, Arizona, United States
Orange County Research Center — Lake Forest, California, United States
Healthy Brain Clinic — Long Beach, California, United States
Valley Clinical Trials, Inc. — Northridge, California, United States
Diablo Clinical Research, Inc. — Walnut Creek, California, United States
Excel Medical Clinical Trials — Boca Raton, Florida, United States
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare — Jacksonville, Florida, United States
L&C Professional Medical Research Institute — Miami, Florida, United States
Global Health Research Center, Inc. — Miami Lakes, Florida, United States
Charter Research - Winter Park — Orlando, Florida, United States
Charter Research - Lady Lake — The Villages, Florida, United States
Balanced Life Health Care Solutions/SKYCRNG — Lawrenceville, Georgia, United States
East-West Medical Research Institute — Honolulu, Hawaii, United States
Bingham Memorial Hospital — Blackfoot, Idaho, United States
Family First Medical Center — Idaho Falls, Idaho, United States
Deaconess Clinic- Gateway — Newburgh, Indiana, United States
Kur Research - Columbia Medical — Columbia, Maryland, United States
Great Lakes Research Group, Inc. — Bay City, Michigan, United States
University of North Carolina Medical Center — Chapel Hill, North Carolina, United States
Remington-Davis, Inc — Columbus, Ohio, United States
Central States Research — Tulsa, Oklahoma, United States
Velocity Clinical Research, Dallas — Dallas, Texas, United States
PlanIt Research, PLLC — Houston, Texas, United States
Activian Clinical Research — Kingwood, Texas, United States
Northwest Clinical Research Center — Bellevue, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.